ACROBiosystems Secures PMDA Material Suitability Confirmation for GMP-Grade IL-15, Streamlining Cell Therapy Approvals in Japan
核心洞察
ACROBiosystems (搜索) received PMDA Material Suitability Confirmation for its GMP-grade recombinant human IL-15 (搜索) protein, validating its safety and compliance for regenerative medicine products.
The certification enables cell therapy developers using this IL-15 (搜索) protein to directly reference the confirmation in Japanese regulatory applications, significantly shortening R&D-to-clinic timelines.
IL-15 (搜索) activates JAK-STAT and PI3K-AKT pathways, enhancing cytotoxic activity, in vivo persistence, and anti-tumor immune memory of T cells and NK cells while reducing cell exhaustion.
ACROBiosystems (搜索) has officially received the "Material Suitability Confirmation for Regenerative Medicine Products" (Certificate No.: 薬機審長発第47号) from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its GMP-grade Human IL-15 (搜索) protein. Announced from Newark, Delaware, this regulatory milestone provides an authoritative endorsement of the company's quality systems and compliance capabilities in the core raw materials field of cell and gene therapy.
The confirmation is part of an official evaluation system established by the PMDA for key raw materials used in the production of regenerative medical products, including CAR-T, CAR-NK, and TCR-T immunotherapies. Its core function is to enable developers to obtain official confirmation of raw material safety and compliance early in the research and development process, thereby streamlining material evaluation during clinical trial or marketing approval applications and accelerating overall product development.
Stringent Certification Requirements
To obtain this confirmation, ACROBiosystems (搜索) met several rigorous conditions: the product and its manufacturing process must not contain human or animal-derived components requiring proof of compliance with the "Guidelines for Biological Raw Materials," or must provide sufficient compliance evidence; the product must be free of physiological active substances, toxic substances, heavy metals, or other components posing direct risks to clinical trial product safety; and the entire production process must operate under a sound quality management system providing complete supply chain traceability and testing validation data.
The confirmation explicitly states that no human or animal-derived components requiring compliance proof with biological raw material guidelines are used in the composition and preparation of this material. The core active ingredient is recombinant human IL-15 (搜索) protein at 0.3 g/L, fully meeting PMDA's safety evaluation requirements.
IL-15 (搜索)'s Role in Cell Therapy Manufacturing
IL-15 (搜索) serves as a key cytokine for high-quality immune cell culture and in vitro functional validation, playing a crucial role in the preparation of CAR-T, CAR-NK, and TCR-T adoptive cell therapies. ACROBiosystems (搜索)' GMP-grade recombinant human IL-15 protein specifically activates downstream JAK-STAT and PI3K-AKT signaling pathways in immune cells, significantly enhancing the cytotoxic activity and in vivo persistence of T cells and natural killer cells. The product effectively improves anti-tumor immune memory and reduces cell exhaustion, while efficiently inducing the expansion and enrichment of high-quality cell subpopulations such as stem cell-like memory T cells (Tscm) and long-lived memory NK cells.
The company has established a complete regulatory support documentation package encompassing material compliance evidence, virus testing validation, and stability study data, providing solid support for developers meeting PMDA application requirements.
Regulatory Impact and Global Reach
On the business front, developers of cell therapies using this IL-15 (搜索) protein can directly reference the PMDA confirmation when applying in Japan, greatly simplifying the evaluation process concerning raw materials and shortening the timeline from research and development to clinical trials. By securing this confirmation from the PMDA—a globally respected authority alongside the FDA and EMA—ACROBiosystems (搜索) demonstrates its commitment to meeting the highest standards required for biopharmaceutical development.
Beyond Japan, ACROBiosystems (搜索) maintains complete regulatory support capabilities in major global markets. All GMP products undergo DMF filing with the FDA in the United States. In China and Europe, where official agencies have yet to open pathways for GMP raw material filings, the company provides comprehensive RSF (Regulatory Support File) documentation to assist customers in drug applications and approvals worldwide. As of April 2026, the company has assisted nearly 30 clients in China, the United States, and South Korea with multiple applications to CDE, FDA, and KFDA.
Quality Management Heritage
ACROBiosystems (搜索) Group has continuously strengthened its quality management infrastructure since its founding in 2010. The group obtained ISO 9001 certification in 2016, ISO 13485 certification in 2018, and established a GMP quality management system in 2021. In 2024, its GMP production site in Suzhou received dual ISO 9001 and GMP certification. In 2025, both the Beijing and Suzhou sites received certification from the RX360 International Pharmaceutical Supply Chain Alliance. The company's experienced quality management team, familiar with biopharmaceutical regulations across different countries and regions, can rapidly establish or improve quality management systems according to varying product types, customer applications, and evolving regulatory requirements.
ACROBiosystems (搜索) Group, listed in 2021, maintains offices, R&D centers, and production bases in more than 15 cities across the United States, Switzerland, the United Kingdom, and Germany, with long-standing partnerships with top pharmaceutical enterprises including Pfizer, Novartis, and Johnson & Johnson.